Stay updated with breaking news from Priority Review. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd., announced today that it has received preliminary analysis results from...
Media contacts: Investor contact: ...
DREAMM-8 results for Blenrep in multiple myeloma featured in a late-breaking presentation and ASCO's Press Programme Updated results from a supported...
VBI Vaccines Inc. , a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new interim tumor response data from the...
The open-label phase 3 ASSURE study evaluated the long-term safety and efficacy of seladelpar in PBC patients who have already participated in other PBC trials of seladelpar.